The Effects of Type 2 Diabetes Mellitus and Hypertension on Survival in Patients with Hepatic Dysfunction and Malignant Solid Tumors
Fatih Tay11Department of Medical Oncology, Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Türkiye
Objectives: The aim of this study was to evaluate the contribution of Type 2 Diabetes Mellitus (T2DM) and hypertension (HT) as comorbidity-enhancing factors on survival in patients with malignant solid tumors who have developed hepatic dysfunction. Methods: Patients who had received treatment in the medical oncology inpatient service between January 01, 2019, and January 01, 2023, and had developed organ insufficiency.. Grading was performe dusing National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. Patients requiring hospitalisation of Grade 3 or higher were included in the evaluation. Results: 66 patients (22%) had T2DM, and 75 patients (25%) had been diagnosed with HT and were undergoing antihypertensive treatment. T2DM patients exhibited a Median Overall Survival (OS) of 7.81 months compared to 16.72 months for non-diabetic patients (p=0.002). Patients with HT had a median OS of 7.85 months compared to 17.41 months for those without HT (p=0.001), indicating significantly higher survival outcomes in those without a diagnosis of HT. Conclusion: It has been demonstrated that T2DM and HT have vital importance in cancer patients, and the regulation of blood sugar levels and blood pressure control play a significant role in survival outcomes. Keywords: Diabetes mellitus, Hypertension, Solid tumors, liver dysfunction
Cite This Article
Tay F. The Effects of Type 2 Diabetes Mellitus and Hypertension on Survival in Patients with Hepatic Dysfunction and Malignant Solid Tumors. EJMI. 2023; 7(4): 341-345
Corresponding Author: Fatih Tay